

TRAVELLERS

Regions where meningococcal meningitis is more common are at increased risk.



Saudi Arabia

Meningitis Belt

Risks to sub-Saharan Africa

Vaccination is recommended before travel to a region from Senegal in the west to Ethiopia in the east (The Meningitis Belt).

Risks with medical conditions

Higher risk if you have one of the following conditions:

- Normal spleen function
- Immunodeficiency
- Recent respiratory tract infection
- Genetic risk factors

If you are travelling soon? Ask your doctor about Nimenrix before you go!



MENINGOCOCCAL MENINGITIS

can be prevented

Ask your doctor about vaccination with Nimenrix



A vaccine, like any medicine, may cause serious problems, such as severe allergic reactions. The risk of Nimenrix causing serious harm is extremely small. The small risks associated with Nimenrix are much less than the risk associated with getting the disease. In infants, adolescents and adults, the most common side effects (reported in more than 1 in 10 doses of the vaccine) after having Nimenrix include loss of appetite, irritability, drowsiness, headache, fever, swelling, pain and redness at the injection site and fatigue. Other common side effects (in more than 1 in 100 doses of the vaccine) after having Nimenrix are gastrointestinal symptoms including diarrhea, vomiting and nausea, and injection site hematoma. Tell your healthcare professional as soon as possible if you or your child does not feel well after receiving Nimenrix. This is not a complete list of side effects. For any unexpected effects while taking Nimenrix, contact your healthcare professional.

Please consult the Product Monograph at www.pfizer.ca/pm/en/Nimenrix.pdf for important information relating to adverse reactions, drug interactions, and dosing information, which have not been discussed in this piece. The Product Monograph is also available by calling 1-800-463-6001.

DIN: 02402904



Nimenrix is a registered trademark of GlaxoSmithKline Biologicals SA, licensed to Pfizer Inc. © 2017 Pfizer Canada Inc., Kirkland, Quebec H9J 2M5

Nimenrix®

TEENS & TRAVELLERS

Are you protected from Meningococcal Meningitis?



Off to college? Planning to travel?

Be proactive and ask your doctor about Nimenrix®

As with all vaccines, Nimenrix may not fully protect all people who are vaccinated. Nimenrix will only protect against infections caused by serogroups of *Neisseria meningitidis* for which the vaccine was developed.




TEENS &

Teens aged 15-19 have among the highest rates of reported invasive meningococcal disease in Canada.

Teens in Canada

After children aged 4 years and under, teens aged 15 to 19 have the highest rate of reported invasive meningococcal disease of any age group in Canada.

Rate per 100,000 of reported invasive meningococcal disease cases by age group in 2015



Teens in crowded places

Meningococcal meningitis has historically occurred in:

- Schools
- Colleges
- Other places where there are large numbers of teens and young adults

Are you a teen heading to a new school? Ask your doctor about Nimenrix before you go!